(225)Actinium-labeled prostate-specific membrane antigen targeting peptide induces complete response in a metastatic prostate cancer patient

Targeted radionuclide therapy has emerged as a promising and potentially curative strategy for high-grade prostate cancer. However, limited data are available on efficacy, quality of life, and pretherapeutic biomarkers. Here, we highlight the case of a patient with prostate-specific membrane antigen...

Descripción completa

Detalles Bibliográficos
Autores principales: Aras, Omer, Harmsen, Stefan, Ting, Richard, Sayman, Haluk B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8172952/
https://www.ncbi.nlm.nih.gov/pubmed/34104479
http://dx.doi.org/10.1177/20584601211022509
_version_ 1783702619620900864
author Aras, Omer
Harmsen, Stefan
Ting, Richard
Sayman, Haluk B
author_facet Aras, Omer
Harmsen, Stefan
Ting, Richard
Sayman, Haluk B
author_sort Aras, Omer
collection PubMed
description Targeted radionuclide therapy has emerged as a promising and potentially curative strategy for high-grade prostate cancer. However, limited data are available on efficacy, quality of life, and pretherapeutic biomarkers. Here, we highlight the case of a patient with prostate-specific membrane antigen (PSMA)-positive metastatic castrate-resistant prostate cancer who displayed complete response to (225)Ac-PSMA-617 after having been resistant to standard-of-care therapy, then initially partially responsive but later resistant to subsequent immunotherapy, and resistant to successive (177)Lu-PSMA-617. In addition, the patient’s baseline germline mutation likely predisposed him to more aggressive disease.
format Online
Article
Text
id pubmed-8172952
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-81729522021-06-07 (225)Actinium-labeled prostate-specific membrane antigen targeting peptide induces complete response in a metastatic prostate cancer patient Aras, Omer Harmsen, Stefan Ting, Richard Sayman, Haluk B Acta Radiol Open Case Report Targeted radionuclide therapy has emerged as a promising and potentially curative strategy for high-grade prostate cancer. However, limited data are available on efficacy, quality of life, and pretherapeutic biomarkers. Here, we highlight the case of a patient with prostate-specific membrane antigen (PSMA)-positive metastatic castrate-resistant prostate cancer who displayed complete response to (225)Ac-PSMA-617 after having been resistant to standard-of-care therapy, then initially partially responsive but later resistant to subsequent immunotherapy, and resistant to successive (177)Lu-PSMA-617. In addition, the patient’s baseline germline mutation likely predisposed him to more aggressive disease. SAGE Publications 2021-05-31 /pmc/articles/PMC8172952/ /pubmed/34104479 http://dx.doi.org/10.1177/20584601211022509 Text en © The Foundation Acta Radiologica 2021 https://creativecommons.org/licenses/by-nc/4.0/Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Case Report
Aras, Omer
Harmsen, Stefan
Ting, Richard
Sayman, Haluk B
(225)Actinium-labeled prostate-specific membrane antigen targeting peptide induces complete response in a metastatic prostate cancer patient
title (225)Actinium-labeled prostate-specific membrane antigen targeting peptide induces complete response in a metastatic prostate cancer patient
title_full (225)Actinium-labeled prostate-specific membrane antigen targeting peptide induces complete response in a metastatic prostate cancer patient
title_fullStr (225)Actinium-labeled prostate-specific membrane antigen targeting peptide induces complete response in a metastatic prostate cancer patient
title_full_unstemmed (225)Actinium-labeled prostate-specific membrane antigen targeting peptide induces complete response in a metastatic prostate cancer patient
title_short (225)Actinium-labeled prostate-specific membrane antigen targeting peptide induces complete response in a metastatic prostate cancer patient
title_sort (225)actinium-labeled prostate-specific membrane antigen targeting peptide induces complete response in a metastatic prostate cancer patient
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8172952/
https://www.ncbi.nlm.nih.gov/pubmed/34104479
http://dx.doi.org/10.1177/20584601211022509
work_keys_str_mv AT arasomer 225actiniumlabeledprostatespecificmembraneantigentargetingpeptideinducescompleteresponseinametastaticprostatecancerpatient
AT harmsenstefan 225actiniumlabeledprostatespecificmembraneantigentargetingpeptideinducescompleteresponseinametastaticprostatecancerpatient
AT tingrichard 225actiniumlabeledprostatespecificmembraneantigentargetingpeptideinducescompleteresponseinametastaticprostatecancerpatient
AT saymanhalukb 225actiniumlabeledprostatespecificmembraneantigentargetingpeptideinducescompleteresponseinametastaticprostatecancerpatient

Ejemplares similares